Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer
Sponsor: Huazhong University of Science and Technology
Listed as NCT03229187, this observational or N/A phase trial focuses on Cervical Cancer and Uterine Cervical Cancer and remains ongoing. Sponsored by Huazhong University of Science and Technology, it has been updated 15 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jul 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Jul 2022 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Recruiting
-
Aug 2019 — Jun 2020 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Apr 2019 — Aug 2019 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Apr 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Huazhong University of Science and Technology
- Wuhan Central Hospital
- Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .